Future vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Future pairs members with 130+ expert human coaches at $199/month using Apple Watch biometrics; 4.9-star rated app with $108M raised ($75M Series C). Founded 2017, San Francisco.
About
Future was founded in 2017 in San Francisco with the mission of making expert personal training accessible to anyone, not just athletes or the wealthy who can afford in-person coaching. The company built a digital personal training platform that pairs each member with a dedicated human coach who designs individualized workout plans, monitors progress through Apple Watch biometric data, and provides real-time feedback through the app. Future's core philosophy is that accountability and personalization — not generic content — are what actually drive sustained behavior change and fitness results.\n\nFuture's platform pairs members with more than 130 expert coaches who have backgrounds in strength and conditioning, sports performance, and clinical exercise science. Coaches review member activity daily, adjust programming based on recovery and performance data, and communicate directly through the app — creating a relationship-driven coaching model at digital scale. The service is priced at $199 per month, positioning it as a premium alternative to both in-person personal training and algorithm-driven fitness apps. Future integrates deeply with Apple Watch to capture heart rate, workout metrics, and activity data, giving coaches objective performance signals to inform programming decisions.\n\nFuture has raised $108 million in total, including a $75 million Series C, and maintains a 4.9-star rating in the App Store across tens of thousands of reviews — a remarkable signal of member satisfaction in a category often plagued by high churn. The company's human-plus-AI coaching model occupies a distinct position between the low-cost digital fitness market and the high-cost in-person coaching market, and its 130-plus coach network gives it a proprietary talent asset that is difficult to replicate. As demand for personalized health and longevity programs grows among high-income professionals, Future's model scales coach capacity through AI-assisted tools while preserving the relational quality that drives retention.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.